哈药股份(600664.SH)发布上半年业绩，归母净利润2.6亿元，同比下降24.37%

Core Viewpoint - Harbin Pharmaceutical Group Co., Ltd. (600664.SH) reported a slight decline in revenue and a significant drop in net profit for the first half of 2025 compared to the previous year [1] Financial Performance - The company achieved an operating income of 8.125 billion yuan, representing a year-on-year decrease of 0.21% [1] - The net profit attributable to shareholders of the listed company was 260 million yuan, down 24.37% year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 244 million yuan, a decrease of 21.71% year-on-year [1] - Basic earnings per share were reported at 0.1 yuan [1]